Squawk Pod: David Sacks, Anthropic, & Regeneron’s deafness cure - 04/24/26 | Audio Only

Summary

The episode covers Intel's massive earnings beat and stock surge, driven by AI chip demand. David Sacks discusses AI policy, the Anthropic-Pentagon dispute, and the xAI-Cursor deal. Regeneron CEO Len Schleifer celebrates FDA approval of a free gene therapy for genetic deafness and highlights the company's valuable genetic database for AI. Other topics include a soldier arrested for insider trading on Polymarket and a New York tax dispute with Citadel.

• Intel reported Q1 earnings of $0.29 per share vs $0.01 expected, revenue $13.6B vs $12.4B, and guided Q2 above consensus; stock surged 28% in after-hours.
• David Sacks, co-chair of the President's Council on Science and Technology, explained the Pentagon's dispute with Anthropic over permissible use of AI in warfare and reiterated the administration's stance against 'woke AI'.
• Sacks commented on the xAI-Cursor partnership, noting the compute shortage and the complementary nature of the deal in the coding AI space.
• Regeneron received FDA approval for Otermony, a gene therapy for a rare form of inherited deafness; the company will provide it free to US patients.
• Regeneron CEO Len Schleifer stated that the company's large genetic database is being sought by AI companies for training, potentially accelerating medical research.
• A US Army soldier was arrested for using classified information to win $400,000 on Polymarket betting on the capture of Venezuelan leader Maduro, raising insider trading questions.
• Citadel criticized New York Mayor Zoran Mandani's proposed tax on high-value second homes owned by non-residents, warning it could jeopardize a major development project.